Eswatini vs Nepal: Average cost of drugs for extensively drug-resistant tuberculosis
Eswatini
2,726 constant 2022 US$
in 2024
Nepal
2,853 constant 2022 US$
in 2024
Eswatini rank
22nd
Nepal rank
21st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Eswatini
- Nepal
How they compare
Nepal currently reports 2,853 constant 2022 US$ against 2,726 constant 2022 US$ in Eswatini, a difference of 127 constant 2022 US$.
The two have swapped places 1 time across 7 shared years of data; in 2018 it was Eswatini ahead.
Eswatini ranks 22nd and Nepal ranks 21st of 56 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eswatini | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20,980 constant 2022 US$ | 2,811 constant 2022 US$ | 18,169 constant 2022 US$ | Eswatini |
| 2020s | 9,624 constant 2022 US$ | 2,995 constant 2022 US$ | 6,630 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Eswatini or Nepal?
- Nepal, at 2,853 constant 2022 US$ against 2,726 constant 2022 US$ in Eswatini as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Eswatini and Nepal?
- 127 constant 2022 US$, with Nepal ahead.
- How many years of comparable data are there for Eswatini and Nepal?
- 7 years are reported by both, from 2018 to 2024.
- How do Eswatini and Nepal rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Eswatini ranks 22nd and Nepal ranks 21st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.